Search by Drug Name or NDC
NDC 00009-7529-05 Camptosar 20 mg/mL Details
Camptosar 20 mg/mL
Camptosar is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Pharmacia & Upjohn Company LLC. The primary component is IRINOTECAN HYDROCHLORIDE.
MedlinePlus Drug Summary
Irinotecan is used alone or in combination with other medications to treat colon or rectal cancer (cancer that begins in the large intestine). Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It works by stopping the growth of cancer cells.
Related Packages: 00009-7529-05Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Irinotecan Injection
Product Information
NDC | 00009-7529 |
---|---|
Product ID | 0009-7529_ece2f47a-8151-4f84-80ec-16cc3a7dec6a |
Associated GPIs | 21550040102030 21550040102025 21550040102035 |
GCN Sequence Number | 062174 |
GCN Sequence Number Description | irinotecan HCl VIAL 100 MG/5ML INTRAVEN |
HIC3 | V3E |
HIC3 Description | ANTINEOPLASTIC - TOPOISOMERASE I INHIBITORS |
GCN | 97956 |
HICL Sequence Number | 010778 |
HICL Sequence Number Description | IRINOTECAN HCL |
Brand/Generic | Brand |
Proprietary Name | Camptosar |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | irinotecan hydrochloride |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | INJECTION, SOLUTION |
Route | INTRAVENOUS |
Active Ingredient Strength | 20 |
Active Ingredient Units | mg/mL |
Substance Name | IRINOTECAN HYDROCHLORIDE |
Labeler Name | Pharmacia & Upjohn Company LLC |
Pharmaceutical Class | Topoisomerase Inhibitor [EPC], Topoisomerase Inhibitors [MoA] |
DEA Schedule | n/a |
Marketing Category | NDA |
Application Number | NDA020571 |
Listing Certified Through | 2024-12-31 |
Package
NDC 00009-7529-05 (00009752905)
NDC Package Code | 0009-7529-05 |
---|---|
Billing NDC | 00009752905 |
Package | 1 VIAL, SINGLE-DOSE in 1 CARTON (0009-7529-05) / 15 mL in 1 VIAL, SINGLE-DOSE |
Marketing Start Date | 1996-06-14 |
NDC Exclude Flag | N |
Pricing Information | N/A |